Onco'Zine

In the dynamic field of cancer research, the hunt for breakthroughs in early disease detection is critical for improving patient outcomes. Exosomes are garnering attention for their potential in cancer diagnostics. The emergence of exosomes and their cargo as important biomarkers in disease monitoring, early discovery, and precision medicine may herald a transformative era in patient care.

Read More

BioQuick News

Biological Dynamics Is Transforming Exosome Research and Advancing Liquid Biopsy with Its Proprietary ExoVerita Pro Platform

Biological Dynamics, a privately held San Diego-based company, is poised to revolutionize exosome/extracellular vesicle (EV) isolation and enrichment by addressing current research challenges and ultimately driving new liquid biopsy advancements. Biological Dynamics has developed an automated bench-top device, ExoVerita Pro, that uses alternating current electrokinetics (ACE) (see details below) to separate exosomes/EVs from other material in small samples of plasma (50-250 µL). The platform offers a simple and automated workflow to enrich exosomes and EVs, bypassing many fundamental limitations of current isolation technologies. This technology is superior to the current exosome/EV separation methods such as ultracentrifugation and column purification in terms of purity and reproducibility and in process time, reducing it from days to hours. 

Read More

GI Oncology Now

Efficacy of Liquid Biopsies Using Extracellular Vesicles for Patients with PDAC

In this interview Dr. Harmeet Dhani, MD, MSc, of Biological Dynamics, highlights his recent publication in Communications Medicine on the benefits of liquid biopsies and why the study investigated the potential of extracellular vesicles protein biomarkers as a detection method for pancreatic cancer. Dr. Dhani also discusses how the study incorporated machine learning and what information was used in the algorithm to help detect PDAC.

Read More

Exosome RNA News

Biological Dynamics and The Pancreatic Cancer Early Detection Consortium (PRECEDE) Collaborate to Improve Surveillance of Early Pancreatic Cancer

Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, and the Pancreatic Cancer Early Detection (PRECEDE) Consortium, an international, multi-institutional group of experts focused on increasing survival rates for pancreatic cancer patients, have signed a multi-year agreement to partner on patient surveillance for early-stage pancreatic cancer using Biological Dynamics’ ExoVita Pancreas Assay, powered by the Verita platform.

Read More

Slice of Healthcare

In this podcast Dr. Billings discusses:

  • Personalized medicine.

  • Biological Dynamics Overview: 10-year-old company, isolates plasma particles from minimal blood samples for diagnostics.

  • Aiming for early-stage detection of pancreatic cancer to improve survival rates.

  • Biological Dynamics unique approach to target exosomes instead of DNA/RNA for richer data; aims to replace invasive tests.

  • Expanding technology to other cancers and potentially Alzheimer’s; involved in clinical trials.

Read More

Exosome RNA News

New Study Demonstrates Efficient Exosome Isolation from Biological Fluids Using Proprietary Technology from Biological Dynamics


Biological Dynamics, a leader in exosome-isolation technology for early disease detection, announced a newly published study in the journal Electrophoresis titled, “Enhancement of Dielectrophoresis-Based Particle Collection from High Conducting Fluids Due to Partial Electrode Insulation.” The collaborative research with Oregon Health & Science University (OHSU) sheds light on the phenomenon occurring on Biological Dynamics’ ExoVerita platform that allows for the capture of biomarkers carried by nanoscale particles.

Read More

Exosome RNA News

Biological Dynamics to Present Data at AACR Highlighting ExoVerita Platform-Enabled Earlier Detection of Pancreatic and Lung Cancers

Biological Dynamics, a life sciences company focused on developing and commercializing exosome isolation technology for earlier disease detection, will present data showing how the company’s ExoVerita™ platform can be utilized for early detection of lung and pancreatic cancers at the American Association of Cancer Research (AACR) annual meeting in Orlando, Fl., April 14-19. A case study of early pancreatic cancer management will also be discussed at the meeting. Biological Dynamics’ will exhibit its technology and early cancer detection assays at booth #1368.

Read More

GenomeWeb

Biological Dynamics: Zach Miller

Biological Dynamics, a San Diego-based company developing exosome-based cancer early detection tests, has appointed Zach Miller to its board of directors. Miller is the founder and managing partner of Parian Global Management. He also previously worked on finance teams a Slate Path Capital and Bain Capital, where he focused on medical and information technology companies. He holds a bachelor's degree from Williams College and a master's degree in philosophy with distinction from Worcester College, Oxford University.

Read More

xCures

How to catch cancer before catching its symptoms. Exo-what?

This week's guest is Dr. Paul Billings, a board-certified internist, renowned researcher, and clinical geneticist. Dr. Billings and Dr. Juneja talk about new methods of early detection of cancer and dive into Dr. Billings's recent research endeavor on exosomes and how they function to identify potentially cancerous cells from a single blood draw, even before symptoms occur. This revolutionary technology aims to redefine cancer

Read More